Charles Schwab Investment Management Inc. Increases Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Charles Schwab Investment Management Inc. grew its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 51.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,336 shares of the biotechnology company's stock after acquiring an additional 37,868 shares during the period. Charles Schwab Investment Management Inc. owned 0.24% of Capricor Therapeutics worth $1,536,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth approximately $3,833,000. Point72 Asset Management L.P. bought a new position in shares of Capricor Therapeutics in the third quarter worth approximately $3,806,000. PFM Health Sciences LP purchased a new stake in shares of Capricor Therapeutics in the third quarter worth $2,324,000. State Street Corp raised its position in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Sphera Funds Management LTD. purchased a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $938,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CAPR. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of CAPR traded up $0.26 during midday trading on Wednesday, hitting $9.74. 1,233,160 shares of the company traded hands, compared to its average volume of 1,425,189. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a 50 day moving average of $13.72 and a 200-day moving average of $15.03. The stock has a market cap of $444.88 million, a price-to-earnings ratio of -9.19 and a beta of 4.09.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. Sell-side analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.